Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347614 | 0.84 | DRD2 (0.39) | TSHRGFERCHRNA7MAPTGLA | |
| SCHEMBL21316789 | 0.84 | DRD2 (0.39) | TSHRGFERCHRNA7MAPTGLA | |
| SCHEMBL408991 | 0.82 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22001607 | 0.82 | GFER (0.41) | TSHRGFERCHRNA7MAPTGLA | |
| SCHEMBL21172116 | 0.82 | THRA (0.38) | TSHRGFERCHRNA7MAPTGLA | |
| SCHEMBL408770 | 0.80 | LMNA (0.40) | MAPTTDP1ALDH1A1SMN1; SMN2GPR119 | |
| SCHEMBL408743 | 0.76 | — | — | |
| SCHEMBL409315 | 0.74 | MEN1 (0.43) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL409342 | 0.73 | MEN1 (0.42) | TSHRMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL408129 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9066967-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024821-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TSHR 2993/4885GFER 2202/4885CHRNA7 3934/4885 |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885GFER 2902/4885CHRNA7 3475/4885 |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | TSHR 1863/4885GFER 4336/4885CHRNA7 1015/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TSHR 2993/4885GFER 2202/4885CHRNA7 3934/4885 |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | TSHR 3728/4885GFER 4183/4885CHRNA7 2799/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885GFER 2902/4885CHRNA7 3475/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885GFER 2902/4885CHRNA7 3475/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885GFER 2902/4885CHRNA7 3475/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | TSHR 1863/4885GFER 4336/4885CHRNA7 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.